Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.71 -5.8%	$6.23	$4.35 ▼ $12.38	$337.31M	0.45	210,474 shs	212,805 shs
CABA Cabaletta Bio	$1.67 -0.6%	$1.79	$0.99 ▼ $7.28	$84.74M	2.7	1.68 million shs	622,840 shs
CAPR Capricor Therapeutics	$6.88 -3.9%	$10.29	$3.52 ▼ $23.40	$314.26M	0.82	2.12 million shs	2.09 million shs
RNAC Cartesian Therapeutics	$11.84 -5.5%	$10.67	$8.46 ▼ $26.50	$307.30M	0.36	97,508 shs	61,404 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	0.00%	+4.84%	+10.00%	+25.19%	-27.22%
CABA Cabaletta Bio	0.00%	-4.02%	-3.47%	+51.82%	-77.91%
CAPR Capricor Therapeutics	0.00%	-9.95%	-42.38%	-38.84%	+42.74%
RNAC Cartesian Therapeutics	0.00%	-11.11%	+18.40%	+12.76%	-35.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	2.4371 of 5 stars	3.6	1.0	2.5	3.3	0.0
CABA Cabaletta Bio	2.8807 of 5 stars	3.5	4.0	2.6	0.8	0.6
CAPR Capricor Therapeutics	2.6215 of 5 stars	4.6	1.0	1.5	0.8	0.6
RNAC Cartesian Therapeutics	2.3191 of 5 stars	3.4	1.0	2.7	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.25	Buy	$22.00	227.87% Upside
CABA Cabaletta Bio	3.00	Buy	$14.43	763.99% Upside
CAPR Capricor Therapeutics	3.11	Buy	$22.56	227.84% Upside
RNAC Cartesian Therapeutics	2.83	Moderate Buy	$40.00	237.84% Upside

Current Analyst Ratings Breakdown

Latest CABA, AURA, CAPR, and RNAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/14/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $12.00
7/11/2025	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00
7/11/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00 ➝ $24.00
7/9/2025	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
6/30/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/26/2025	CAPR Capricor Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
6/25/2025	CAPR Capricor Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/25/2025	CAPR Capricor Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $29.00
6/24/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00
6/23/2025	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$43.00 ➝ $22.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$3.12 per share	N/A
CAPR Capricor Therapeutics	$22.27M	14.11	N/A	N/A	$3.20 per share	2.15
RNAC Cartesian Therapeutics	$38.91M	7.90	N/A	N/A	($0.27) per share	-43.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/14/2025 (Estimated)
CABA Cabaletta Bio	-$115.86M	-$2.54	N/A	N/A	N/A	N/A	-78.29%	-65.68%	8/6/2025 (Estimated)
CAPR Capricor Therapeutics	-$40.47M	-$1.42	N/A	N/A	N/A	-181.71%	-62.42%	-48.36%	8/6/2025 (Estimated)
RNAC Cartesian Therapeutics	-$77.42M	-$52.83	N/A	N/A	N/A	N/A	N/A	-7.01%	8/6/2025 (Estimated)

Latest CABA, AURA, CAPR, and RNAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AURA Aura Biosciences	-$0.47	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	CABA Cabaletta Bio	-$0.71	N/A	N/A	N/A	N/A	N/A
8/14/2025	N/A	RNAC Cartesian Therapeutics	-$0.77	N/A	N/A	N/A	$0.77 million	N/A
8/6/2025	Q2 2025	CAPR Capricor Therapeutics	-$0.48	N/A	N/A	N/A	$2.60 million	N/A
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/13/2025	Q1 2025	CAPR Capricor Therapeutics	-$0.33	-$0.53	-$0.20	-$0.53	$3.16 million	$2.73 million
5/8/2025	Q1 2025	RNAC Cartesian Therapeutics	-$0.61	-$0.68	-$0.07	-$0.68	$0.69 million	$1.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	11.06	11.06
CABA Cabaletta Bio	N/A	3.96	3.96
CAPR Capricor Therapeutics	N/A	6.55	6.55
RNAC Cartesian Therapeutics	N/A	12.34	12.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
CABA Cabaletta Bio	N/A
CAPR Capricor Therapeutics	21.68%
RNAC Cartesian Therapeutics	86.95%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	5.40%
CABA Cabaletta Bio	11.25%
CAPR Capricor Therapeutics	10.50%
RNAC Cartesian Therapeutics	60.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
CABA Cabaletta Bio	50	50.74 million	45.03 million	Optionable
CAPR Capricor Therapeutics	101	45.68 million	40.88 million	Optionable
RNAC Cartesian Therapeutics	64	25.95 million	10.30 million	Optionable

CABA, AURA, CAPR, and RNAC Headlines

Recent News About These Companies

Q2 Earnings Forecast for RNAC Issued By Wedbush

July 13, 2025 | americanbankingnews.com

Cartesian Therapeutics (NASDAQ:RNAC) Coverage Initiated by Analysts at Wedbush

July 12, 2025 | americanbankingnews.com

Brokers Set Expectations for RNAC Q2 Earnings

July 11, 2025 | marketbeat.com

Wedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform Recommendation

July 9, 2025 | msn.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 9, 2025 | marketbeat.com

Cartesian Therapeutics (NASDAQ:RNAC) Earns Outperform Rating from Analysts at Wedbush

July 9, 2025 | marketbeat.com

We're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate

June 21, 2025 | finance.yahoo.com

Cartesian Therapeutics holds annual stockholders meeting

June 17, 2025 | investing.com

Cartesian Therapeutics Announces New Employment Inducement Grants

June 3, 2025 | globenewswire.com

BTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

June 2, 2025 | theglobeandmail.com

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 30, 2025 | globenewswire.com

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 13, 2025 | manilatimes.netM

Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 11, 2025 | finance.yahoo.com

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential

May 5, 2025 | insidermonkey.com

Cartesian Therapeutics Announces New Employment Inducement Grants

May 2, 2025 | globenewswire.com

Cartesian Therapeutics management to meet with BTIG

April 26, 2025 | markets.businessinsider.com

Why Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 5.62%

April 22, 2025 | aaii.comA

Why Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 6.62%

April 15, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
Buybacks Galore: Repurchases From the Oval Office to Olive Garden
By Leo Miller | June 30, 2025
View Buybacks Galore: Repurchases From the Oval Office to Olive Garden
3 Fast Food Stocks That Won’t Give You Indigestion Right Now
By Brian O'Connell | July 16, 2025
View 3 Fast Food Stocks That Won’t Give You Indigestion Right Now
Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback
By Thomas Hughes | June 23, 2025
View Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback
How Texas Roadhouse Is Winning in a Changing Consumer Market
By Dan Schmidt | July 14, 2025
View How Texas Roadhouse Is Winning in a Changing Consumer Market

CABA, AURA, CAPR, and RNAC Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.71 -0.41 (-5.76%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$6.86 +0.15 (+2.16%)

As of 07/18/2025 06:50 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Cabaletta Bio NASDAQ:CABA

$1.67 -0.01 (-0.60%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.68 +0.02 (+0.90%)

As of 07/18/2025 07:50 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Capricor Therapeutics NASDAQ:CAPR

$6.88 -0.28 (-3.91%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$6.91 +0.03 (+0.44%)

As of 07/18/2025 07:59 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Cartesian Therapeutics NASDAQ:RNAC

$11.84 -0.69 (-5.51%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$12.15 +0.31 (+2.62%)

As of 07/18/2025 07:56 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time